Clinical Investigators Urge FDA to Approve Capricor’s Deramiocel
A public letter from clinical investigators urged FDA approval of Capricor Therapeutics’ Deramiocel. Capricor shares rose roughly 14% on Tuesday; the FDA decision is upcoming.
Shares of Capricor Therapeutics (CAPR) climbed roughly 14% on Tuesday as a public letter from clinical investigators added momentum ahead of a pivotal regulatory decision on the company’s therapy Deramiocel.The FDA is slated to decide on approving the drug for the treatment of Duchenne muscular dys…